Journal Home
Search for

Volume 152, Issue 6, Pages 290-297 (December 2008)


View previous. 10 of 12 View next.

Quantitative real-time polymerase chain reaction (qRT-PCR) restriction fragment length polymorphism (RFLP) method for monitoring highly conserved transgene expression during gene therapy

Carol M. Bruzzone, John D. Belcher, Nathan J. Schuld, Kristal A. Newman, Julie Vineyard, Julia Nguyen, Chunsheng Chen, Joan D. Beckman, Clifford J. Steer, Gregory M. VercellottiCorresponding Author Informationemail address

Received 1 August 2008; received in revised form 6 October 2008; accepted 8 October 2008. published online 06 November 2008.

Evaluation of the transfer efficiency of a rat heme oxygenase-1 (HO-1) transgene into mice requires differentiation of rat and mouse HO-1. However, rat and mouse HO-1 have 94% homology; antibodies and enzyme activity cannot adequately distinguish HO-1. We designed a quantitative real-time polymerase chain reaction (qRT-PCR) method to monitor HO-1 transcription relative to a housekeeping gene, GAPDH. The ratio of rat and mouse HO-1 mRNA could be estimated through restriction fragment length polymorphism (RFLP) analysis of the PCR products. In vitro, murine AML12 hepatocytes were transfected with rat HO-1. After 40 h, the total HO-1 mRNA was enriched 2-fold relative to control cells, and rat HO-1 comprised 84% of HO-1 cDNA. In vivo, the rat HO-1 transgene was cloned into a Sleeping Beauty transposase (SB-Tn) construct and was injected hydrodynamically into a mouse model of sickle cell disease (SCD). After 21 days, there was a 32% enrichment of HO-1 mRNA relative to control mice and the rat transgene comprised 88% of HO-1 cDNA. After 21 days, HO-1 protein expression in liver was increased 2.5-fold. In summary, qRT-PCR RFLP is a useful and reliable method to differentiate the transgene from host gene transcription, especially when the host and transgene protein are identical or highly homologous. This method has translational applications to the design, delivery, and monitoring of gene-therapy vectors.

Department Medicine and Vascular Biology Center, University of Minnesota, Minneapolis, Minn

Corresponding Author InformationReprint requests: Gregory M. Vercellotti, Department of Medicine, University of Minnesota, MMC 480, 420 Delaware Street SE, Minneapolis, MN 55455

 Supported by Grant PO1 HL55552 from the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI).

PII: S1931-5244(08)00246-6

doi:10.1016/j.trsl.2008.10.005


View previous. 10 of 12 View next.